Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: September 2025
Principal Executive Office: Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. As a development stage enterprise, the document focuses on corporate events rather than financial performance data.
Material Changes
No material financial changes versus a prior comparable period are disclosed in this filing. The report serves to incorporate an announcement regarding a corporate presentation.
Guidance, Outlook, and Management Commentary
- Corporate Event: Alterity Therapeutics is scheduled to present at the Biotech Showcase (Exhibit 99.1).
- Registration Statements: This Form 6-K is incorporated by reference into Registration Statements on Form S-8 (Files No. 333-251073, 333-248980, 333-228671) and Form F-3 (Files No. 333-274816, 333-251647, 333-231417, 333-250076).
- Risks and Contingencies: No specific risks or contingencies are detailed in this summary document.
Investor Verification Checklist
- Verify the date and agenda of the upcoming Biotech Showcase presentation referenced in Exhibit 99.1.
- Review the referenced Form S-8 and Form F-3 registration statements for details on equity offerings or employee compensation plans.
- Confirm the company's current cash runway and burn rate in the most recent Form 20-F or quarterly report, as this 6-K contains no financial data.